DennisKendallBurnsMD

Pathology • Dallas, TX

Neuropathology, Anatomic Pathology, Clinical Pathology

Professor of Pathology, UT Southwestern Medical Center

Join to view full profile

Dr. Burns is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Burns' full profile

Already have an account?

Office
5323
Harry Hines BLVD
Dallas, TX 75390
Phone+1 214-648-1620

Fax+1 214-648-4080

Education & Training

University of Texas Southwestern Medical CenterResidency, Pathology-Anatomic and Clinical, 1984 - 1985
University of Texas Southwestern Medical CenterResidency, Pathology-Anatomic and Clinical, 1979 - 1983
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1978 - 1978
University of Texas Southwestern Medical SchoolClass of 1978

Certifications & Licensure

TX State Medical License 1978 - 2025
American Board of Pathology Anatomic Pathology & Clinical Pathology
American Board of Pathology Neuropathology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Publications & Presentations

PubMed

Myxovirus resistance protein A (MxA) expression in myositides: Sarcoplasmic expression is common in both dermatomyositis and lupus myositis.
Changhong Xing, Jaya Trivedi, Nicole Bitencourt, Dennis K Burns, Joan S Reisch
Muscle & Nerve. 2024-05-01
1 citations
Ectopic PLAG1 induces muscular dystrophy in the mouse.
Juan Shugert Aguayo, John M Shelton, Wei Tan, Dinesh Rakheja, Chunyu Cai
Biochemical and Biophysical Research Communications. 2023-07-12
Port-Wine Stain and Monomelic Weakness Associated With Perineurioma: A Neuromuscular Image.
Jenny Riecke, Avneesh Chhabra, Dennis Burns, Jaya R Trivedi
Journal of Clinical Neuromuscular Disease. 2022-03-01

Press Mentions

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory PapillomatosisSeptember 13th, 2023